Aduro Gvax Inc.
Records under this name other than patents Aduro Gvax Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,919,079 | Cancer Immunotherapy Compositions and Methods of Use Formerly held In force · High confidence | In force | High confidence | |
| US 8,580,247 | PS-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof Formerly held In force · USPTO record | In force | USPTO record | |
| US 7,901,902 | Methods and Compositions for Identifying a Cellular Immune Response Against Prostate Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 9,669,081 | Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer Formerly held In force · High confidence | In force | High confidence | |
| US 8,840,881 | Methods and Compositions for Treating Prostate Cancer or Inducing a Humoral Immune Response Against Prostate Cancer Formerly held Lapsed on the fee record Ended Sep 23, 2026 · High confidence | Lapsed on the fee record | Ended Sep 23, 2026 | High confidence |
| US 7,176,022 | Directly injectable formulations which provide enhanced cryoprotection of cell products Formerly held Term ended Term ended Feb 27, 2024 · USPTO record | Term ended | Term ended Feb 27, 2024 | USPTO record |
| US 9,848,598 | Cryoprotected, frozen recombinant cancer cells Formerly held Term ended Ended no later than Dec 20, 2022 · USPTO record | Term ended | Ended no later than Dec 20, 2022 | USPTO record |
| US 8,287,856 | PD-1 Antibodies in Combination with a Cytokine-Secreting Cell and Methods of Use Thereof Lapsed on the fee record Ended Oct 16, 2020 · Medium confidence | Lapsed on the fee record | Ended Oct 16, 2020 | Medium confidence |
| US 9,433,204 | Directly injectable formulations which provide enhanced cryoprotection of cell products Lapsed on the fee record Ended Sep 6, 2020 · USPTO record | Lapsed on the fee record | Ended Sep 6, 2020 | USPTO record |
| US 7,645,587 | Novel Cancer-Associated Antigens and Methods of Their Identification and Use Term ended Term ended Nov 3, 2019 · Medium confidence | Term ended | Term ended Nov 3, 2019 | Medium confidence |